- Global Pharma News & Resources

Betül Susamis Unaran leaves Zur Rose Group

Zur Rose Group AG / Key word(s): Personnel
Betül Susamis Unaran leaves Zur Rose Group
31.05.2022 / 07:00

Frauenfeld, 31 May 2022
Press Release

Betül Susamis Unaran leaves Zur Rose Group

Betül Susamis Unaran, Chief Strategy and Digital Officer as well as member of the Executive Board, has decided to pursue new career paths and leave the Zur Rose Group. In her almost three-year tenure, Ms. Unaran has been instrumental in the successful positioning of the Zur Rose Group and its transformation into the European healthcare ecosystem. In particular, she shaped and drove the rebranding of the DocMorris umbrella brand as well as the development of Health Journeys for people with obesity and diabetes. The Executive Board thanks her for her great commitment and wishes her all the best for her private and professional future.

The implementation of the ecosystem strategy will be driven forward in all areas of the Zur Rose Group. The development of strategic partnerships will continue under the leadership of Anouk Robert, Group Director Partnerships and Branding.

Investors and analyst contact
Christoph Herrmann, Head of Investor Relations
Email:, phone: +41 58 810 11 49

Media contact
Maike Schöffel, Senior Communications and Investor Relations Manager
Email:, phone: +41 52 724 15 49

18 August 2022 Half-Year Results
20 October 2022 Q3 Trading Update

Zur Rose Group
The Swiss Zur Rose Group is Europe’s largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany’s best-known pharmacy brand, DocMorris, and employs more than 2,400 people at sites in Switzerland, Germany, the Netherlands, Spain and France. Now serving more than 12 million active customers in core European markets, Zur Rose generated external revenue of CHF 2,034 million in 2021.

With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care, as well as digital services relating to marketplaces, ecosystems, technology and telemedicine. In addition, Zur Rose is actively driving forward its positioning as a comprehensive healthcare service provider, with focus on building up and extending its European healthcare ecosystem networking qualified providers of products, services and digital solutions. Its ambition is to provide customer-centred health journeys so people are offered optimum supply and a range of medication and treatment options. By doing so, Zur Rose is pursuing its vision of creating a world where people can manage their own health in one click.

The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information, please visit

End of Media Release

Language: English
Company: Zur Rose Group AG
Walzmühlestrasse 60
8500 Frauenfeld
Phone: +41 52 724 08 14
ISIN: CH0042615283
Listed: SIX Swiss Exchange
EQS News ID: 1360061

End of News EQS News Service

Editor Details

Last Updated: 31-May-2022